DVAX - NASDAQ
Dynavax Technologies Corporation
$15.50
+0.0000%Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
At a Glance
Live SnapshotDynavax Technologies Corporation Management Team
Mr. Ryan Spencer
Chief Executive Officer & Director
Compensation
$1,484,326
Dr. Robert Janssen M.D.
Chief Medical Officer and Senior Vice President of Clinical Development, Medical & Regulatory Affairs
Compensation
$827,719
Mr. David F. Novack
President & Chief Operating Officer
Compensation
$965,313
Mr. Donn Casale
Senior Vice President & Chief Commercial Officer
Mr. Jeff P. Coon
Senior Vice President & Chief Human Resources Officer
Mr. John L. Slebir
Senior Vice President & General Counsel
Compensation
$809,129
Dr. Dong Yu
Senior Vice President of Research
Ms. Kelly MacDonald CPA
Senior Vice President, Principal Accounting Officer & Chief Financial Officer
Compensation
$733,501
Mr. Paul Cox
Vice President of Investor Relations & Corporate Communications
Mr. Eric Frings
Vice President, Site Head & MD for Dynavax GmbH
Dynavax Technologies Corporation Insider Positioning
During the last 12 months, insiders have purchased $41K and sold $24.60M worth of DVAX shares, resulting in $24.56M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
144.0K
2.25M
-2.2M
-$2.25M
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
3.8K
41.12K
2.1M
22.35M
-22.3M
-$22.31M
Top Buyers
Myers Scott Dunseth
Director
$41K
Top Sellers
Deep Track Biotechnology Master Fund, Ltd.
10 Percent Owner
$22.35M
Novack David F
Officer: President & Coo
$2.25M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $24.56M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
2 insider sellers vs. 1 buyers. More insiders selling than buying suggests cautious or negative sentiment.
SEC Filings
DVAX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2024 N/A | April 11, 2024 | May 23, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 13, 2023 | April 13, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 14, 2022 | May 26, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 16, 2021 | May 28, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 17, 2020 | May 28, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 22, 2019 | May 30, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 20, 2018 | May 31, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | July 10, 2017 | July 31, 2017 | 2017 | |
DEF 14A DEF 14A 2017 N/A | April 21, 2017 | May 31, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | April 22, 2016 | May 31, 2016 | 2016 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.